Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company's lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/21/20 | $3,000,000 | Series A |
Kenneth Kelley | undisclosed |
